News and Announcements
DomaCom is Supporting a Federal Court Action Appealing for its Sub-Funds
- Published June 05, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
DomaCom is supporting a Federal Court action appealing for its sub-funds to be considered in-house assets or related trusts under the SIS (Superannuation Industry Supervision) Act.
KEY TAKEAWAYS:
- If successful, SMSF investors with the ASX-listed fractional investment fund manager would be able to invest in property sub-funds in which the tenant of the underlying property is in some way a related party of the SMSF.
- In seeking the determination DomaCom believes it will play a key role in helping people use their superannuation to access the property market while still protecting the assets of the SMSF.
- The Federal Court action follow years of working to help solve the issue of housing affordability for young people.
“The unique arm’s length structure of the DomaCom Fund protects the SMSF assets whilst generating commercial rates of income and capital return that the underlying property delivers,” DomaCom chief executive Arthur Naoumidis said.
“Residential property can be used as an anchor asset class for the superannuation portfolios of Generation X and Y investors which can then expand to other asset classes later in life. The Gen X/Y investors can then rent the property and acquire more of the interest in the related sub-fund as time goes on.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
